Preclinical Safety Testing for New Drugs
Europe’s premier toxicology and safety pharmacology preclinical event
Informa Life Sciences’ 4th Annual Preclinical Safety Testing for New Drugs will deliver practical strategies and real life examples concerning:
- Preclinical regulatory updates
- Translatability to clinical studies
- Toxicity studies
- Innovations in preclinical safety testing
- Safety Pharmacology
- Drug:drug interactions
This conference must be attended to stay at the forefront of preclinical safety testing.
2010 Conference Highlights
Brand new topics for 2010 include:
- Exploring integration of additional endpoints in preclinical toxicology studies
- Exploring the value of combining toxicity with safety pharmacology for cardiovascular studies
- Preclinical safety testing for topical dermal products
Expert Speaker Pannel
-
Speakers confirmed so far include:
Expert Speaker Pannel
Klaus Olejniczak
Head of Genetic and Reproduction Toxicology Unit
BfArM
|
Peter Heining
Executive Director Project Safety, TS, PCS
Novartis Instutue for Biomedical Research
|
Stephane Dhalluin
Director, Investigative Non-Cliincal Safety
UCB Pharma
|
John Foster
Senior Prinicipal Pathologist, Safety Assessment
AstraZeneca
|
Wilhelm Haverkamp
Vice Director, Department of Cardiology
Charite Universite
|
- Klaus Olejniczak, Head of Genetic and Reproduction Toxicology Unit, BfArM (Federal Institute for Drugs and Medical Devices), Germany
- Vasily N. Dobrovolsky, Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US FDA (Food and Drug Administration), USA
- Peter Heining, Dr. med. vet., Executive Director Project Safety, Translational Sciences (TS); Preclinical Safety (PCS), Novartis Institute for Biomedical Research, Switzerland
- Claudia Stark, Head of Systemic and Reproduction Toxicology Nonclinical Drug Safety, Bayer Schering Pharma AG, Germany
- Sandra Johanssen, Global Preclinical Development, Intendis GmbH, Germany
- Corina-Dana Dota, Clinical Research Physician, Cardiac (QT/Arrhythmia) Safety Knowledge Group Co-chair, AstraZeneca, Sweden
- John Foster, Senior Principal Pathologist, Safety Assessment, AstraZeneca, UK
- Paul Jones, Non-Clinical Safety Manager, Drug Development Office Department, Cancer Research UK, UK
- Ben Sykes, Senior Programme Manager, National Stem Cell Network (UKNSCN), UK
- Wilhelm Haverkamp, Vice Director, Department of Cardiology, Charite University, Germany
- Gilles Hanton, Former Senior Director Preclinical Toxicology, Johnson & Johnson, France
Speaking opportunities still available
Please contact:
Sarah Palit
Senior Conference Producer
Informa- Life Sciences (formerly IIR & IBC)
Tel: +44 (0) 20 7017 5371
Email: sarah.palit@informa.com
Connect with me on LinkedIn!
http://www.linkedin.com/in/sarahpalit
Dates and Venues
01 Dec 2010 - 02 Dec 2010
Andel's Hotel Berlin
